Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Activation of the proapoptotic receptor death receptor5 (DR5) in various cancer cells triggers programmed cell death through the extrinsic pathway. We have generated a fully human monoclonal antibody (Apomab) that induces tumor cell apoptosis through DR5 and investigated the structural features of its interaction with DR5. Biochemical studies showed that Apomab binds DR5 tightly and selectively. X-ray crystallographic analysis of the complex between the Apomab Fab fragment and the DR5 ectodomain revealed an interaction epitope that partially overlaps with both regions of the Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand binding site. Apomab induced DR5 clustering at the cell surface and stimulated a death-inducing signaling complex containing the adaptor molecule Fas-associated death domain and the apoptosis-initiating protease caspase-8. Fc crosslinking further augmented Apomab's proapoptotic activity. In vitro, Apomab triggered apoptosis in cancer cells, while sparing normal hepatocytes even upon anti-Fc crosslinking. In vivo, Apomab exerted potent antitumor activity as a single agent or in combination with chemotherapy in xenograft models, including those based on colorectal, non-small cell lung and pancreatic cancer cell lines. These results provide structural and functional insight into the interaction of Apomab with DR5 and support further investigation of this antibody for cancer therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, death receptor-targeted therapies (e.g., DR4/DR5 agonist antibodies) were shown to enhance the antitumor activity of chemotherapy drugs (5-FU, irinotecan) in CRC xenograft models [145,146,147].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [146]
Citations
Cites
1 retracted
RETRACTED: Death-receptor activation halts clathrin-dependent endocytosis
Austin, C. D., Lawrence, D. A., Peden, A. A., Varfolomeev, E. E., Totpal, K., De Mazière, A. M., Klumperman, J., Arnott, D., Pham, V., Scheller, R. H., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604044103 · Cited by 112 · cited 15×
“We used the phage display approach to develop a fully human, affinity-matured IgG1/l3 monoclonal antibody (called Apomab) that triggers apoptosis upon interaction with human DR5.”
ResultSelf-citationRetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Thornberry, N. A., & Lazebnik, Y. (1998) · Science · doi:10.1126/science.281.5381.1312 · Cited by 6,887 · cited 1×
“caspase-3, -6 and -7), which drive the apoptotic cell death program.(10,11) Two principal signaling pathways control cellular caspase activation: the intrinsic pathway is initiated”
BackgroundDeath Receptors: Signaling and Modulation
Ashkenazi, A., & Dixit, V. M. (1998) · Science · doi:10.1126/science.281.5381.1305 · Cited by 5,866 · cited 1×
“these receptors can trigger apoptosis in various types of cancer cells, while sparing most normal cell types.(17,20) Two molecular types of proapoptotic receptor agonists (PARAs) that target”
BackgroundSelf-citation[19] Rapid and efficient site-specific mutagenesis without phenotypic selection
Kunkel, T. A., Roberts, J. D., & Zakour, R. A. (1987) · Methods in Enzymology · doi:10.1016/0076-6879(87)54085-x · Cited by 5,261
Nagata, S. (1997) · Cell · doi:10.1016/s0092-8674(00)81874-7 · Cited by 4,938
Danial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651
Estimates of the cancer incidence and mortality in Europe in 2006
Ferlay, J., Autier, P., Boniol, M., Heanue, M., Colombet, M., & Boyle, P. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl498 · Cited by 4,036
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
Fulda, S., & Debatin, K.-M. (2006) · Oncogene · doi:10.1038/sj.onc.1209608 · Cited by 2,312 · cited 1×
“these receptors can trigger apoptosis in various types of cancer cells, while sparing most normal cell types.(17,20) Two molecular types of proapoptotic receptor agonists (PARAs) that target”
BackgroundSafety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Self-citationDeath and anti-death: tumour resistance to apoptosis
Igney, F. H., & Krammer, P. H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc776 · Cited by 2,075
IAP proteins: blocking the road to death's door
Salvesen, G. S., & Duckett, C. S. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm830 · Cited by 1,756 · cited 1×
“adaptor Apaf-1 to activate initiator caspase-9, and Smac/ Diablo, which antagonizes blockade of caspase-9 and of effector caspases by inhibitor of apoptosis proteins.(15) Taken”
BackgroundControl of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors
Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C. L., Baker, K., Wood, W. I., et al. (1997) · Science · doi:10.1126/science.277.5327.818 · Cited by 1,664
Self-citationPresta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,608
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
Ashkenazi, A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc821 · Cited by 1,360 · cited 2×
“apoptosis resistance mechanism associated with inactivation of p53 in cancer cells.(3) The proapoptotic receptors DR4 and DR5 are of unique interest because initiation of apoptosis”
BackgroundSelf-citationTargeting Apoptosis Pathways in Cancer Therapy
Ghobrial, I. M., Witzig, T. E., & Adjei, A. A. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.3.178 · Cited by 1,330
Lowe, S. W., Cepero, E., & Evan, G. (2004) · Nature · doi:10.1038/nature03098 · Cited by 1,309 · cited 1×
“cancer, oncogene activation and genotoxic damage drive apoptosis; however, frequent inactivation of the p53 tumor suppressor – a crucial conduit between certain types of cellular damage and apoptosis – often enables tumor cells to escape apoptotic death.(8,9) Apoptosis is carried out by specialized proteases called ca…”
BackgroundOsteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL
Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14363 · Cited by 1,184
Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak
Willis, S. N., Fletcher, J. I., Kaufmann, T., van Delft, M. F., Chen, L., Czabotar, P. E., Ierino, H., Lee, E. F., Fairlie, W. D., Bouillet, P., et al. (2007) · Science · doi:10.1126/science.1133289 · Cited by 1,125
Promoting apoptosis as a strategy for cancer drug discovery
Fesik, S. W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1736 · Cited by 1,098
Apo2L/TRAIL and its death and decoy receptors
LeBlanc, H. N., & Ashkenazi, A. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401187 · Cited by 854
Self-citationThe machinery of programmed cell death
Zimmermann, K. C., Bonzon, C., & Green, D. R. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(01)00159-0 · Cited by 833 · cited 1×
“caspase-3, -6 and -7), which drive the apoptotic cell death program.(10,11) Two principal signaling pathways control cellular caspase activation: the intrinsic pathway is initiated”
BackgroundDifferential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D., Mounho, B., Hillan, K., Totpal, K., DeForge, L., Schow, P., et al. (2001) · Nature Medicine · doi:10.1038/86397 · Cited by 702
Self-citationA novel receptor for Apo2L/TRAIL contains a truncated death domain
Marsters, S. A., Sheridan, J. P., Pitti, R. M., Huang, A., Skubatch, M., Baldwin, D., Yuan, J., Gurney, A., Goddard, A. D., Godowski, P., et al. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00422-2 · Cited by 653
Self-citationWagner, K. W., Punnoose, E. A., Januario, T., Lawrence, D. A., Pitti, R. M., Lancaster, K., Lee, D., von Goetz, M., Yee, S. F., Totpal, K., et al. (2007) · Nature Medicine · doi:10.1038/nm1627 · Cited by 612 · cited 11×
“We used the phage display approach to develop a fully human, affinity-matured IgG1/l3 monoclonal antibody (called Apomab) that triggers apoptosis upon interaction with human DR5.”
BackgroundSelf-citationTumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity
Ichikawa, K., Liu, W., Zhao, L., Wang, Z., Liu, D., Ohtsuka, T., Zhang, H., Mountz, J. D., Koopman, W. J., Kimberly, R. P., et al. (2001) · Nature Medicine · doi:10.1038/91000 · Cited by 543
Hymowitz, S. G., Christinger, H. W., Fuh, G., Ultsch, M., O'Connell, M., Kelley, R. F., Ashkenazi, A., & de Vos, A. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80207-5 · Cited by 435
Self-citationTargeting death receptors in cancer with Apo2L/TRAIL
KELLEY, S. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.02.006 · Cited by 370 · cited 1×
“Efficacy of rhApo2L/ TRAIL in preclinical cancer models has been documented, demonstrating compelling antitumor activity both as monotherapy and in combination with chemotherapy.(3,23) Here, we describe Apomab, a DR5 agonist antibody, determine the structure of its Fab fragment in complex with DR5 and characterize its…”
BackgroundSelf-citationTolcher, A. W., Mita, M., Meropol, N. J., von Mehren, M., Patnaik, A., Padavic, K., Hill, M., Mays, T., McCoy, T., Fox, N. L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8898 · Cited by 314
Pukac, L., Kanakaraj, P., Humphreys, R., Alderson, R., Bloom, M., Sung, C., Riccobene, T., Johnson, R., Fiscella, M., Mahoney, A., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602487 · Cited by 306
Targeted Therapies for Cancer 2004
Ross, J. S., Schenkein, D. P., Pietrusko, R. G., Rolfe, M., Linette, G. P., Stec, J. J., Stagliano, N. E., Ginsburg, G. S., Symmans, W. F., Pusztai, L., et al. (2004) · American Journal of Clinical Pathology · doi:10.1309/5cwp-u41a-fr1v-ym3f · Cited by 286
Kelley, R. F., Totpal, K., Lindstrom, S. H., Mathieu, M., Billeci, K., DeForge, L., Pai, R., Hymowitz, S. G., & Ashkenazi, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410660200 · Cited by 284 · cited 1×
“This result agrees with earlier studies assessing the proapoptotic activity of receptorselective rhApo2L/TRAIL mutants against solid tumor-derived cell lines.(42) On the other hand, it has recently been reported that there may be certain types of leukemia, for example, chronic lymphocytic leukemia, in which DR4 activa…”
ResultSelf-citationA Unique Zinc-Binding Site Revealed by a High-Resolution X-ray Structure of Homotrimeric Apo2L/TRAIL
Hymowitz, S. G., O'Connell, M. P., Ultsch, M. H., Hurst, A., Totpal, K., Ashkenazi, A., de Vos, A. M., & Kelley, R. F. (2000) · Biochemistry · doi:10.1021/bi992242l · Cited by 261 · cited 2×
“has a negative effect on Apo2L/TRAIL bioactivity and results in impaired binding affinity for DR5 as well as DR4.(34) The Apomab–DR5 interface is centered in a nearly continuous region of DR5, comprising residues 62–90, with additional”
BackgroundSelf-citationJones, E. Y., Mongkolsapaya, J., Grimes, J. M., Chen, N., Xu, X., Stuart, D. I., & Screaton, G. R. (1999) · Nature Structural Biology · doi:10.1038/14935 · Cited by 253
Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers
Plummer, R., Attard, G., Pacey, S., Li, L., Razak, A., Perrett, R., Barrett, M., Judson, I., Kaye, S., Fox, N. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0950 · Cited by 247
The role of the Bcl-2 protein family in cancer
Coultas, L., & Strasser, A. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00129-3 · Cited by 242
Lee, C. V., Liang, W.-C., Dennis, M. S., Eigenbrot, C., Sidhu, S. S., & Fuh, G. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.05.051 · Cited by 227 · cited 1×
“coli and purified over a protein G affinity column.(49,50) Fabcontaining fractions were further purified by passage over a SP-Sepharose column (Pharmacia).”
MethodGanten, T. M., Koschny, R., Sykora, J., Schulze-Bergkamen, H., Büchler, P., Haas, T. L., Schader, M. B., Untergasser, A., Stremmel, W., & Walczak, H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2635 · Cited by 217
Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4
Chuntharapai, A., Dodge, K., Grimmer, K., Schroeder, K., Marsters, S. A., Koeppen, H., Ashkenazi, A., & Kim, K. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.8.4891 · Cited by 202
Self-citationRowinsky, E. K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2889 · Cited by 197
Georgakis, G. V., Li, Y., Humphreys, R., Andreeff, M., O'Brien, S., Younes, M., Carbone, A., Albert, V., & Younes, A. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05656.x · Cited by 171
TRAIL Receptor-Selective Mutants Signal to Apoptosis via TRAIL-R1 in Primary Lymphoid Malignancies
MacFarlane, M., Kohlhaas, S. L., Sutcliffe, M. J., Dyer, M. J. S., & Cohen, G. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2801 · Cited by 163 · cited 1×
“On the other hand, it has recently been reported that there may be certain types of leukemia, for example, chronic lymphocytic leukemia, in which DR4 activation may be more important to achieve significant efficacy.(43) Notwithstanding, there may also even be some clinical scenarios in which engaging both DR4 and DR5…”
Background2.8 Å Resolution Crystal Structure of Human TRAIL, a Cytokine with Selective Antitumor Activity
Cha, S.-S., Kim, M.-S., Choi, Y. H., Sung, B.-J., Shin, N. K., Shin, H.-C., Sung, Y. C., & Oh, B.-H. (1999) · Immunity · doi:10.1016/s1074-7613(00)80100-4 · Cited by 158
Motoki, K., Mori, E., Matsumoto, A., Thomas, M., Tomura, T., Humphreys, R. C., Albert, V. R., Muto, M., Yoshida, H., Aoki, M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1867 · Cited by 106
Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2
Mori, E., Thomas, M., Motoki, K., Nakazawa, K., Tahara, T., Tomizuka, K., Ishida, I., & Kataoka, S. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401331 · Cited by 93 · cited 1×
“Hepatocytes have been noted as a normal cell type that can be susceptible to apoptosis activation by FasL, or several non-optimized Apo2L/TRAIL preparations,(39,40) or certain DR4 or DR5 antibodies.(41) We found that Apomab did not stimulate any detectable caspase activation in cultured hepatocytes, whether or not it…”
BackgroundGuo, Y., Chen, C., Zheng, Y., Zhang, J., Tao, X., Liu, S., Zheng, D., & Liu, Y. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503621200 · Cited by 85
Zhang, L., Zhang, X., Barrisford, G. W., & Olumi, A. F. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.11.013 · Cited by 54
Trail Receptor-Targeted Therapy
Buchsbaum, D. J., Zhou, T., & LoBuglio, A. F. (2006) · Future Oncology · doi:10.2217/14796694.2.4.493 · Cited by 52
A Method for Storing Controls for Prothrombin-Time Determinations*
Davis, V., & Eilert, M. L. (1952) · American Journal of Clinical Pathology · doi:10.1093/ajcp/22.6_ts.598 · Cited by 3
Cited by
Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy
von Karstedt, S., Montinaro, A., & Walczak, H. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.28 · Cited by 556
Directing cancer cells to self-destruct with pro-apoptotic receptor agonists
Ashkenazi, A. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2637 · Cited by 432
Self-citationTargeting the extrinsic apoptosis pathway in cancer
Ashkenazi, A. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.04.001 · Cited by 418
“Enhanced activity for this combination over either agent alone was observed as well in mice bearing LS180 or DLD-1 colon xenografts [29].”
BackgroundMethodInfluentialSelf-citationPhage display-derived human antibodies in clinical development and therapy
Frenzel, A., Schirrmann, T., & Hust, M. (2016) · mAbs · doi:10.1080/19420862.2016.1212149 · Cited by 346
“Drozitumab (Apomab, PRO95780, Roche/Genentech) was also generated by phage display from a human scFv library against TRAIL-R2.(137) A Phase 1 study demonstrated safety in humans at doses up to 20 mg/kg and evidence of activity in several different tumor types at 4 and 10 mg/kg.”
MethodInfluentialTo kill a tumor cell: the potential of proapoptotic receptor agonists
Ashkenazi, A., & Herbst, R. S. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34359 · Cited by 323
Self-citation
Metadata
- Authors
- Adams, C., Totpal, K., Lawrence, D., Marsters, S., Pitti, R., Yee, S., Ross, S., Deforge, L., Koeppen, H., Sagolla, M., Compaan, D., Lowman, H., Hymowitz, S., & Ashkenazi, A.
- Affiliations
- Genentech (US)
- Corresponding author
- Ashkenazi, A
- Venue
- Cell Death & Differentiation
- Published
- 2008-01-25
- Volume
- 15
- Issue
- 4
- Pages
- 751-761
- ISSN
- 1350-9047 (ISSN-L)
- 1476-5403
- OpenAlex
- W2074106785
- Cited by
- 148
- References
- 51
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 2 · 2023: 7 · 2022: 1 · 2021: 8 · 2020: 5 · 2019: 6 · 2018: 4 · 2017: 9 · 2016: 9 · 2015: 11 · 2014: 7 · 2013: 19 · 2012: 12
- FWCI
- 6.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cell Death and Differentiation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- DR5, agonistic monoclonal antibody, antigen-antibody reaction, extrinsic apoptotic pathway, TRAIL receptors, FADD, caspase-8, receptor clustering, selective cytotoxicity, anticancer activity, colorectal cancer, non-small cell lung cancer, pancreatic cancer
- MeSH terms
- Animals, Antibodies, Monoclonal, Antibody Affinity, Antibody Specificity, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Binding Sites, Antibody, Dose-Response Relationship, Drug, Female, Humans, Mice, Nude, Models, Molecular, Neoplasms, Experimental, Protein Binding, Protein Conformation, Receptor Aggregation, Time Factors, Signal Transduction, Apoptosis, Crystallography, X-Ray, Epitope Mapping, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Caspase 8, Fas-Associated Death Domain Protein, Receptors, TNF-Related Apoptosis-Inducing Ligand
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.